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Acute myeloid leukemia (AML) is an aggressive form of cancer that occurs in 
hematopoietic stem cells. Previous work demonstrated that AML tumors contain many 
recurrent mutations. Some of these mutations occur in genes that are critical for epigenetic 
regulation, such as DNMT3A, TET2, or IDH1 and IDH2 (collectively referred to as IDH). 
Mutations in IDH occur in about 20% of AML samples. Mutant IDH enzyme develops 
neomorphic function; it produces the oncometabolite 2-hydroxyglutarate (2HG) instead 
of alpha-ketoglutarate. 2HG has been associated with DNA hypermethylation and 
increased histone methylation in AML. Both epigenetic changes alter the chromatin 
state, which can affect gene expression. Our lab hypothesizes that expression of mutant 
IDH2 alleles increases the amount and type of methylation at genomic loci that can 
affect the transcription of genes with promoters located in differentially methylated 
regions (DMRs) of IDH mutant and wild type AML. To assess mutant IDH2-specific 
dysregulation, our lab developed a line of transgenic H9 human embryonic stem (hES) 
cells with a doxycycline (DOX)-inducible IDH2R140Q mutant allele. We optimized DOX 
treatment for both expression of the mutant allele and cell viability by manual counting 
with a hemocytometer and then confirmed by mass spectrometry that mutant IDH2 
produces 2HG. As for changes in methylation, we demonstrated by Western blotting 
that expression of mutant IDH2 increases overall trimethylated H3K9, a histone marker 
of gene silencing. We are currently preparing transgenic hES cell DNA for TrueMethyl 
bisulfite and oxidative bisulfite sequencing to quantify and locate DNA methylation. 
To understand differences in expression due to methylation, we took a subset of 871 
unique gene promoters located in the DMRs of DNA. Using RNA-Seq data, we identified 
nineteen genes with dysregulation beyond what would be predicted. PANTHER Gene 
List Analysis of the 871 unique genes identified consistent themes for protein and nucleic 
acid binding as well as hydrolase and transferase activity.
